Cargando…
Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy
Aberrant fibroblast growth factor receptor (FGFR) activation/expression is a common feature in lung cancer (LC). In this study, we evaluated the antitumor activity of and the mechanisms underlying acquired resistance to two potent selective FGFR inhibitors, AZD4547 and BAY116387, in LC cell lines. T...
Autores principales: | Kim, S-M, Kim, H, Yun, M R, Kang, H N, Pyo, K-H, Park, H J, Lee, J M, Choi, H M, Ellinghaus, P, Ocker, M, Paik, S, Kim, H R, Cho, B C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399172/ https://www.ncbi.nlm.nih.gov/pubmed/27429073 http://dx.doi.org/10.1038/oncsis.2016.48 |
Ejemplares similares
-
Patient Selection Approaches in FGFR Inhibitor Trials—Many Paths to the Same End?
por: Ellinghaus, Peter, et al.
Publicado: (2022) -
MET-Pyk2 Axis Mediates Acquired Resistance to FGFR Inhibition in Cancer Cells
por: Kitowska, Kamila, et al.
Publicado: (2021) -
Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer
por: Frigault, Melanie M., et al.
Publicado: (2020) -
Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
por: Fujino, Toshio, et al.
Publicado: (2021) -
Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion
por: Kim, Sun Young, et al.
Publicado: (2017)